Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Feb;34(2):1137-1145.
doi: 10.1007/s00330-023-10073-9. Epub 2023 Aug 24.

MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients

Affiliations
Multicenter Study

MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients

Daniel M Düx et al. Eur Radiol. 2024 Feb.

Abstract

Objective: To assess the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment extra-abdominal desmoids.

Methods: A total of 105 patients with desmoid fibromatosis (79 females, 26 males; 35 ± 14 years) were treated with MRgFUS between 2011 and 2021 in three centers. Total and viable tumors were evaluated per patient at last follow-up after treatment. Response and progression-free survival (PFS) were assessed with (modified) response evaluation criteria in solid tumors (RECIST v.1.1 and mRECIST). Change in Numerical Rating Scale (NRS) pain and 36-item Short Form Health Survey (SF-36) scores were compared. Treatment-related adverse events were recorded.

Results: The median initial tumor volume was 114 mL (IQR 314 mL). After MRgFUS, median total and viable tumor volume decreased to 51 mL (95% CI: 30-71 mL, n = 101, p < 0.0001) and 29 mL (95% CI: 17-57 mL, n = 88, p < 0.0001), respectively, at last follow-up (median: 15 months, 95% CI: 11-20 months). Based on total tumor measurements (RECIST), 86% (95% CI: 75-93%) had at least stable disease or better at last follow-up, but 50% (95% CI: 38-62%) of remaining viable nodules (mRECIST) progressed within the tumor. Median PFS was reached at 17 and 13 months for total and viable tumors, respectively. NRS decreased from 6 (IQR 3) to 3 (IQR 4) (p < 0.001). SF-36 scores improved (physical health (41 (IQR 15) to 46 (IQR 12); p = 0.05, and mental health (49 (IQR 17) to 53 (IQR 9); p = 0.02)). Complications occurred in 36%, most commonly 1st/2nd degree skin burns.

Conclusion: MRgFUS reduced tumor volume, reduced pain, and improved quality of life in this series of 105 patients with extra-abdominal desmoid fibromatosis.

Clinical relevance statement: Imaging-guided ablation is being increasingly used as an alternative to surgery, radiation, and medical therapy for the treatment of desmoid fibromatosis. MR-guided high-intensity focused ultrasound is an incisionless ablation technique that can be used to reduce tumor burden effectively and safely.

Key points: • Desmoid fibromatosis was treated with MR-guided high-intensity focused ultrasound in 105 patients. • MR-guided focused ultrasound ablation reduced tumor volume and pain and improved quality of life. • MR-guided focused ultrasound is a treatment option for patients with extra-abdominal desmoid tumors.

Keywords: Ablation techniques; Fibromatosis, aggressive; Musculoskeletal diseases; Neoplasms, connective and soft tissue.

PubMed Disclaimer

References

    1. Reitamo JJ, Hayry P, Nykyri E, Saxen E (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. https://doi.org/10.1093/ajcp/77.6.665
    1. Bonvalot S, Desai A, Coppola S, et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. https://doi.org/10.1093/annonc/mds298
    1. Anneberg M, Svane HML, Fryzek J, et al (2022) The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol. https://doi.org/10.1016/j.canep.2022.102114
    1. Colombo C, Fiore M, Grignani G, et al (2022) A prospective observational study of Active surveillance in primary desmoid fibromatosis. Clin Cancer Res 28(18):4027–4032. https://doi.org/10.1158/1078-0432.CCR-21-4205
    1. Schut AW, Timbergen MJM, van Broekhoven DLM, et al (2022) A nationwide prospective clinical trial on active surveillance in patients with non-intra-abdominal desmoid-type fibromatosis: the GRAFITI Trial. Ann Surg. https://doi.org/10.1097/SLA.0000000000005415

Publication types

LinkOut - more resources